ライフサイエンスコーパス: CLABSI

1 CLABSI data reported to NHSN from 2009 to 2012 from adul

2 CLABSI detection by AI methods was at least as accurate

3 CLABSI incidence rates were compared using Poisson regre

4 CLABSI-POA is associated with significant in-hospital mo

5 CLABSI-POA was defined using an adaptation of the acute

6 CLABSIs and VAEs increased by 24% and 34%, respectively,

7 CLABSIs remain a significant problem in neonatal and ped

8 CLABSIs, VAEs, and CDIs increased significantly during t

9 ys within 3 days of a CLABSI (a total of 217 CLABSIs).

10 and physicians retrospectively reviewed 220 CLABSI/non CLABSI bacteremias.

11 ne bathing period, 55 infections occurred: 4 CLABSI, 21 CAUTI, 17 VAP, and 13 C difficile.

12 ol bathing period, 60 infections occurred: 4 CLABSI, 32 CAUTI, 8 VAP, and 16 C difficile.

13 mentation CLABSI rates ranged from 0 to 71.4 CLABSIs per 1000 catheter-days.

14 During 2009-2012, 4654 CLABSIs were reported to NHSN from 299 adult oncology un

15 rate was low and decreased from 0.88 to 0.80 CLABSI per 1000 catheter-days.

16 (odds ratio [OR], 1.36; 95% CI, 1.01-1.83), CLABSI (OR, 6.39; 95% CI, 3.02-13.52), and apheresis (OR

17 ing this period there were a total of 10,866 CLABSI cases and 9,543,765 central line days.

18 A total of 282 patients (3.4%) experienced a CLABSI (mean [IQR] age, 1.34 [0.07-8.83] years; female,

19 ients with a total of 375,078 CVC-days for a CLABSI incidence rate of 1.63 per 1,000 CVC-days (95% CI

20 CCs were significantly more likely to have a CLABSI (HR = 1.6; 95% CI, 1.2-2.2; P = .002) and CVC mal

21 nts, with 639 device days within 3 days of a CLABSI (a total of 217 CLABSIs).

22 profile, antimicrobial resistance rates, and CLABSI incidence rates per 1000 central line-days were c

23 es are associated with the burden of VAP and CLABSI in LMICs.

24 VAP and CLABSI were reported in accordance with Brazilian regula

25 ere associated with reduced rates of VAP and CLABSI.

26 -effectiveness was determined by calculating CLABSIs prevented and incremental cost-effectiveness rat

27 efined using an adaptation of the acute care CLABSI definition.

28 The most common organisms causing CLABSI in oncology locations were coagulase-negative sta

29 one resistance was more common among E. coli CLABSI in oncology than nononcology locations (56.5% vs

30 t in 334/2301 (14.5%) HO-ASEs, most commonly CLABSIs (6.0% of HO-ASEs), C. difficile (5.0%), and CAUT

31 mportant strategy to include in contemporary CLABSI-prevention bundles.

32 atios, or 2 x 2 tables of DTP for diagnosing CLABSI.

33 artificial intelligence (AI) may facilitate CLABSI identification.

34 For CLABSI, the incidence for the full 9 quarters of the stu

35 population occurred in quarter 3 of 2020 for CLABSI (11.0 vs 7.3), quarter 4 of 2021 for CAUTI (7.8 v

36 y for VAP and 44.7% (95% CI, 35.0-54.5%) for CLABSI.

37 06) for VAP and 3.53 (95% CI, 2.30-4.76) for CLABSI.

38 ed the diagnostic characteristics of DTP for CLABSI using MEDLINE, Embase, WoS, CINAHL, LILACS, AMED,

39 eneralized linear mixed model regression for CLABSI events.

40 day is associated with an increased risk for CLABSI and that a significant fraction of CL access may

41 ontributed a 6.3% increase in daily risk for CLABSI.

42 BSI in the community to identify targets for CLABSI prevention initiatives outside acute care setting

43 tive personnel, are at an increased risk for CLABSIs.

44 cantly associated with an increased risk for CLABSIs.

45 al of 461 patients were identified as having CLABSI-POA.

46 BCC was associated with higher CLABSI rates in ICUs.

47 ociated with increased risk for reported ICU CLABSI.

48 h system and was associated with declines in CLABSI consistent with published clinical trial findings

49 The study's findings show disparities in CLABSI rates for Black patients and patients who speak a

50 the non-COVID-19 population, the increase in CLABSI incidence vs the 2019 incidence was eliminated, a

51 ial lock solutions led to a 69% reduction in CLABSI rate (relative risk [RR], 0.31; 95% confidence in

52 rventions were associated with reductions in CLABSI rates in neonates and children by a half or more,

53 studied, affected the relative reduction in CLABSIs, which also remained significant among studies r

54 h have resulted in significant reductions in CLABSIs and their associated adverse outcomes.

55 No significant reductions in CLABSIs have been noted with the use of either.

56 e of hospital acquired conditions, including CLABSIs.

57 health care-associated infections including CLABSIs, CAUTIs, VAP, or C difficile.

58 ntral line-associated bloodstream infection (CLABSI) pathogens and antimicrobial resistance patterns

59 ntral line-associated bloodstream infection (CLABSI) rates by how central line days are counted: once

60 ntral line-associated bloodstream infection (CLABSI) rates.

61 ntral line-associated bloodstream infection (CLABSI) remains prevalent in hospitals in the United Sta

62 ntral line-associated bloodstream infection (CLABSI) with each other and as compared with simplified

63 ntral line-associated bloodstream infection (CLABSI), catheter-associated urinary tract infection (CA

64 ntral line-associated bloodstream infection (CLABSI), central venous catheter, or apheresis was assoc

65 ntral line-associated bloodstream infection (CLABSI), Clostridioides difficile infection, mortality,

66 ntral line-associated bloodstream infection (CLABSI).

67 tral line-associated blood stream infection (CLABSI) surveillance is mandated and publicly reported i

68 ntral-line associated bloodstream infection [CLABSI] and vancomycin use).

69 A history of invasive bacterial infection, CLABSI, or a central line appears to be associated with

70 tral line-associated bloodstream infections (CLABSI) per 1000 device days.

71 ral line-associated blood stream infections (CLABSI), catheter-associated urinary tract infections (C

72 tral line-associated bloodstream infections (CLABSIs) and (2) patients with community-onset pneumonia

73 tral line-associated bloodstream infections (CLABSIs) and other healthcare-acquired infections.

74 tral line associated bloodstream infections (CLABSIs) are a common source of morbidity and mortality

75 tral line-associated bloodstream infections (CLABSIs) are not fully understood.

76 tral line-associated bloodstream infections (CLABSIs) in neonates and children.

77 tral line-associated bloodstream infections (CLABSIs) in patients maintaining central venous catheter

78 tral line-associated bloodstream infections (CLABSIs) may lead to modifications to central line (CL)

79 tral line-associated bloodstream infections (CLABSIs) often result from intraluminal microbial coloni

80 tral line-associated bloodstream infections (CLABSIs), and catheter malfunctions in PICCs and TLs, an

81 tral-line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (

82 tral line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (

83 tral line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (

84 tral line-associated bloodstream infections (CLABSIs), using National Healthcare Safety Network surve

85 tral line-associated bloodstream infections (CLABSIs), we performed a systematic search of PubMed, Em

86 tral line-associated bloodstream infections (CLABSIs).

87 lassification of bloodstream infections into CLABSI by the CDC's definition and present the financial

88 Despite the low CLABSI incidence of 0.41/1000 CVC-days in patients rando

89 ol availability were associated with a lower CLABSI rate.

90 (95% confidence interval [CI]: 23-108%) more CLABSI, 43% (95% CI: 8-90%) more CAUTI, and 44% (95% CI:

91 ians retrospectively reviewed 220 CLABSI/non CLABSI bacteremias.

92 ance is required to understand the burden of CLABSI in the community to identify targets for CLABSI p

93 imary endpoint consisted of the incidence of CLABSI and intracatheter thrombolytic treatment (TT).

94 point committee adjudicated the incidence of CLABSI.

95 ution significantly reduced the incidence of CLABSI.

96 r lock solutions may reduce the incidence of CLABSI.

97 Independent predictors of CLABSI late complications included intensive care unit (

98 s in a given CL device day and prevalence of CLABSI within the following 3 days.

99 tions to heparin locks for the prevention of CLABSI in 3 settings: hemodialysis, cancer treatment, an

100 an effective strategy for the prevention of CLABSI, and their use can result in significant healthca

101 of antimicrobial locks for the prevention of CLABSI.

102 The estimated rate of CLABSI decreased by 23.5% (95% confidence interval, 9.8%

103 Rates of CLABSI and device utilization ratio pre- and postinterve

104 Rates of CLABSI decreased from 1.8 to 1.1 per 1000 central venous

105 Furthermore, rates of CLABSI were significantly higher in oncology compared to

106 timodal intervention did not reduce rates of CLABSI.

107 es was independently associated with risk of CLABSI in the next 3 days (adjusted odds ratio, 1.007; 9

108 ses is independently associated with risk of CLABSI in the next 3 days.

109 solutions are effective in reducing risk of CLABSI, and this effect appears to be additive to tradit

110 We performed a retrospective cohort study of CLABSI surveillance using standardized prompts, clinical

111 To clarify the burden of CLABSIs in these patients, we characterized patients wit

112 al line insertion and maintenance bundles on CLABSI rates in neonatal and pediatric intensive care un

113 regression analysis at the hospital level on CLABSI-observed cases by ICUs in acute care hospitals (n

114 A IPs from different facilities to report on CLABSI using their usual surveillance methods.

115 CDC's National Healthcare Safety Network on CLABSIs in intensive care units (ICUs), at over 4,000 Me

116 sociated with mortality for either PNEUMO or CLABSI patients.

117 or the home parenteral nutrition setting per CLABSI episode prevented.

118 Monthly preimplementation CLABSI rates ranged from 0 to 71.4 CLABSIs per 1000 cath

119 Recurrent CLABSIs occurred in a quarter of patients (25%).

120 itical care networks to significantly reduce CLABSI rates.

121 Quality improvement interventions to reduce CLABSI are an important component of patient safety init

122 e data indicate a recent decline in reported CLABSI rates, likely secondary to changes in diagnostic

123 iated with an increased risk of ICU reported CLABSIs.

124 DTP performs well in ruling CLABSIs in or out.

125 Among 2526 suspected CLABSIs, DTP demonstrated a summary sensitivity of 81.3%

126 of 236 and 100 patients were included in the CLABSI and PNEUMO cohorts, respectively.

127 Over the study period, the unadjusted CLABSI rate was low and decreased from 0.88 to 0.80 CLAB

128 ly higher incidence of catheter-related VTE, CLABSI, and CVC malfunction over TLs.

129 creased in all phases of the pandemic, while CLABSIs increased in later phases of the pandemic.

130 rds, classification was more consistent with CLABSI assigned in a proportion ranging from 36% to 42%

131 ese patients, we characterized patients with CLABSI present on hospital admission (POA).

132 ve cross-sectional analysis of patients with CLABSI-POA in 3 health systems covering 11 hospitals acr

133 Among patients with CLABSI-POA, mortality risk increased with age (hazard ra

134 of patient records that 18 IPs reported with CLABSI ranged from 14% to 39% (overall mean, 28% with a

135 USA100 strain (P = .02), whereas those with CLABSI were more likely to die if they were older (P < .